VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Safety and efficacy of teclistamab in patients with triple-class exposed R/R myeloma

Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, shares some insights into the safety and efficacy of teclistamab in patients with triple-class exposed relapsed/refractory (R/R) myeloma as observed in the MajesTEC-1 trial (NCT04557098), and further highlights the importance of optimizing treatment with this bispecific T-cell engager (BiTE). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter